IRIS Registry data showed no change in anti-VEGF frequency, vision, or retinal thickness after patients with DME began a GLP-1RA.

Jordi Monés, MD, PhD, explains why RP and Stargardt data support testing son-vec to restore vision in advanced GA.

Veeral Sheth, MD, breaks down the LUCIA wet AMD data, plus new AAO findings on GLP-1 agents and anti-VEGF treatment burden in DME.

AREDS-based review links Mediterranean diet adherence to slower AMD and GA progression, as a complement to AREDS2 supplements.

Luma, an eye-tracking and assessment tool, helps eye care professionals gain objective insights into visual performance.

Phase 3 SLO-RP Preserve will test whether oral NPI-001 slows photoreceptor loss in retinitis pigmentosa due to Usher syndrome.

FDA grants orphan drug designation to oral OCT-980 for RHO-adRP, now in phase 1b/2 testing at US sites.

Patients with atrial fibrillation (AF) had measurable structural retinal changes in a large international study.